See the findings on XCOPRI safety
MOST COMMON ADVERSE REACTIONS (≥10% FOR XCOPRI AND GREATER THAN PLACEBO)1
FOR PATIENTS TAKING 200 MG/DAILY OF XCOPRI (RECOMMENDED MAINTENANCE DOSAGE)*
XCOPRI 100 mg/day (n=108)
and XCOPRI 400 mg/day (n=111);
somnolence, 19% and 37%;
dizziness, 18% and 33%;
fatigue, 12% and 24%;
diplopia, 6% and 15%;
headache 10% and 10%.
This is not a full list of safety information.
For more information, see Full Prescribing Information.
Study design (Open-Label Extension Analysis)2
Study 2 was a randomized, double-blind, placebo-controlled study in adult patients with partial-onset seizures with an OLE phase. An analysis of the OLE data evaluated the long-term safety and efficacy (up to 48 months] of adjunctive XCOPRI® (cenobamate tablets) CV. Patients with uncontrolled focal seizures despite concomitant treatment with 1 to 3 ASMs who completed the 18-week double-blind study (n=360) could enter the OLE (n=355), where they underwent a 2-week blinded conversion to a target dosage of XCOPRI 300 mg/day. Doses of concomitant ASMs could be adjusted during the conversion phase. During the OLE treatment phase, concomitant ASMs could be added, removed, or adjusted (no cenobamate monotherapy allowed) and the XCOPRI dosage could be increased or decreased, if clinically indicated, to a minimum of 50 mg/day and a maximum of 400 mg/day. Scheduled OLE assessments occurred every 3 months. Safety assessments included evaluation of treatment-emergent adverse events, including frequency, seriousness, timing, and those leading to discontinuation.
MANAGING ADJUNCTIVE THERAPY
Managing the concomitant use of XCOPRI
The Adjunctive Use of XCOPRI: Demystified
In this interactive video, watch as Lawrence Seiden, MD, and Barry Gidal, PharmD, discuss anti‑seizure medication (ASM) dosing considerations to be aware of when adding XCOPRI to a patient’s treatment regimen. Discover essential information regarding the optimization of XCOPRI’s efficacy, plus potential ways to minimize side effects—and be sure to bookmark for reference.
XCOPRI® (cenobamate tablets) CV makes the
concentration of some drugs go up. Consider
decreasing the dosage of clobazam, phenytoin,
and phenobarbital earlier in XCOPRI titration1,2
*Examples include lacosamide, levetiracetam, brivaracetam, perampanel, eslicarbazepine, and topiramate.
FIND MORE INFORMATION FOR PRESCRIBING XCOPRI WITH CONCOMITANT MEDICATIONS